
Recce Pharmaceuticals Investor Relations Material
Latest events

Investor Update
Recce Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Recce Pharmaceuticals Ltd
Access all reports
Recce Pharmaceuticals Ltd is an Australian biotechnology company specializing in the development of synthetic anti-infectives to treat serious and hard-to-treat infections. The company’s proprietary technology focuses on creating broad-spectrum antibiotics designed to address antibiotic-resistant bacteria and viral infections. Recce’s primary products target bacterial sepsis, bloodstream infections, and other drug-resistant infections. Its approach to antimicrobial development aims to tackle the global challenge of antibiotic resistance through innovative, synthetic compounds that enhance treatment efficacy. The company is headquartered in Sydney, Australia, and its shares are listed on the ASX.
Key slides for Recce Pharmaceuticals Ltd


AGM 2024
Recce Pharmaceuticals Ltd


AGM 2024
Recce Pharmaceuticals Ltd
Latest articles
)
The Rise and Fall of Wirecard
A look inside the Wirecard scandal, which took the company from the prestigious DAX 30 to insolvency through the largest accounting fraud in European history.
16 May 2025
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
Ticker symbol
RCE
Country
🇦🇺 Australia